---
title: "Coherus Oncology (CHRS) news: convertible notes and Nasdaq notice"
url: "https://aibio.space/companies/coherus-oncology/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "CHRS convertible notes, Nasdaq notice and buyback news: Coherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025."
---

CHRS Coherus Oncology, Inc. NASDAQ · United States

# Coherus Oncology (CHRS) news CHRS convertible notes, Nasdaq notice and buyback news

Debt Financing · 2026-08-17

## [Coherus Oncology takes $55,000,000 senior secured term loan to refinance debt](https://aibio.space/news/coherus-oncology-takes-55-000-000-senior-secured-term-loan-refinance/)

Innovatus Life Sciences Lending Fund I, LP, is collateral agent on a loan that replaces an existing term loan and runs to August 2031, with interest-only payments for an initial 36 months.

## Latest Coherus Oncology news

1. 2025-09-08 Listings [Coherus Oncology regains Nasdaq compliance with $1.00 minimum bid price rule](https://aibio.space/news/coherus-oncology-regains-nasdaq-compliance-1-00-minimum-bid-price-rule/) Nasdaq closed the matter on September 5, 2025, ahead of the December 29, 2025 deadline the company had been given.
2. 2025-07-03 Listings [Coherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025](https://aibio.space/news/coherus-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Nasdaq told Coherus on June 30, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until December 29, 2025 to regain compliance, while its cash, cash equivalents and marketable securities were $126.0 million at December 31, 2024 against $230.0 million of 2026 convertible notes.
3. 2025-04-14 Mergers [Coherus BioSciences (now Coherus Oncology) completes UDENYCA sale, gets $483.4 million upfront](https://aibio.space/news/coherus-biosciences-now-coherus-oncology-completes-udenyca-sale-gets/) Coherus received $483.4 million in cash at the April 11, 2025 closing and says it has a $250 million post-close cash balance. It is eligible for milestone payments of up to $75 million.
4. 2025-04-14 Mergers [Coherus (now Coherus Oncology) completes UDENYCA sale to Intas for $483.4 million upfront](https://aibio.space/news/coherus-now-coherus-oncology-completes-udenyca-sale-intas-483-4/) Coherus can earn up to $75 million more in sales milestones and says it has $250 million in cash after closing, enough to fund work into 2027.
5. 2025-04-01 Financings [Coherus (now Coherus Oncology) to repurchase about $170 million of convertible notes](https://aibio.space/news/coherus-now-coherus-oncology-repurchase-about-170-million-convertible/) The buyback depends on closing the sale of the UDENYCA franchise. Coherus plans to buy back the remaining $60 million after that deal closes.
6. 2025-01-14 Mergers [Coherus BioSciences (now Coherus Oncology) seeks vote on $483.4 million UDENYCA sale](https://aibio.space/news/coherus-biosciences-now-coherus-oncology-seeks-vote-483-4-million/) Coherus could also earn two $37.5 million payments if UDENYCA sales hit set targets. The board unanimously recommends a vote for the sale.

## Coherus Oncology at a glance

- **Ticker**: CHRS

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $105.3 million

### Related companies

- [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) NASDAQ: APRE
- [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) NASDAQ: ABOS
- [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT
- [Rafarma Pharmaceuticals, Inc. (WY)](https://aibio.space/companies/rafarma-pharmaceuticals-wy/) OTC: RAFA
- [Windtree Therapeutics](https://aibio.space/companies/windtree-therapeutics/) OTC: WINT
- [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) NASDAQ: PRAX
- [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) NASDAQ: OKUR
- [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) NASDAQ: PTCT

### Also on NASDAQ

- [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) CGEM
- [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) PPCB
- [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) BRVE
- [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB
- [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) TPST
- [Neurogene](https://aibio.space/companies/neurogene/) NGNE

## What Coherus Oncology does

Coherus Oncology, Inc. is a fully integrated commercial-stage oncology company focused on immuno-oncology. Its approved product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody developed with Junshi Biosciences Co., Ltd. The company announced on October 27, 2023 that the FDA had approved LOQTORZI for first-line nasopharyngeal carcinoma (NPC) with cisplatin and gemcitabine and as monotherapy for recurrent or metastatic NPC after platinum-containing chemotherapy. The company says it is the only immune checkpoint inhibitor approved by the FDA for these indications that is commercially available in the United States. Its strategy is to grow LOQTORZI sales in NPC and to pursue new indications in combination with its pipeline and partners' agents. Casdozokitug (CHS-388), an antagonist antibody targeting IL-27, is in a randomized Phase 2 study in hepatocellular carcinoma. Tagmokitug (CHS-114), an afucosylated IgG1 antibody targeting CCR8, is in clinical studies in head and neck squamous cell carcinoma and advanced solid tumors. The company changed its name from Coherus BioSciences, Inc. in May 2025 after divesting its biosimilar businesses.

| Product or program | What it is | Stage |
|---|---|---|
| LOQTORZI (toripalimab-tpzi) | Anti-PD-1 antibody for nasopharyngeal carcinoma | approved in the US |
| Casdozokitug (CHS-388) | IL-27 antagonist antibody for hepatocellular carcinoma and other cancers | randomized Phase 2 |
| Tagmokitug (CHS-114) | Afucosylated IgG1 antibody targeting CCR8 on regulatory T cells | Phase 1b; Phase 2a cohort |

Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm).

## Coherus Oncology annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$108.9 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) | [$91.8 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) |
| Net income (loss) | [$168.0 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) | [$28.5 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) |
| Cash from operations | [-$138.5 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) | [-$20.4 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) |
| Cash and equivalents | [$88.9 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/) | [$126.0 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/) |
| Short-term investments | [$83.2 million](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/) |  |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $82.9 million, plus short-term investments of $22.4 million, $105.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Coherus Oncology

Has Coherus Oncology sold convertible notes?

Our latest story on this, dated Jul 3, 2025: "Coherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/coherus-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/).

Has Coherus Oncology received a Nasdaq deficiency notice?

Our latest story on this, dated Jul 3, 2025: "Coherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/coherus-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/).

Does Coherus Oncology have a share buyback?

Our latest story on this, dated Apr 1, 2025: "Coherus (now Coherus Oncology) to repurchase about $170 million of convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/coherus-now-coherus-oncology-repurchase-about-170-million-convertible/).

What is the ticker symbol of Coherus Oncology?

Coherus Oncology, Inc. trades under the ticker CHRS on NASDAQ.

Where is Coherus Oncology listed?

Coherus Oncology, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8C5; LSX:A12ETZ.

What is the SEC CIK of Coherus Oncology?

The SEC Central Index Key (CIK) for Coherus Oncology, Inc. is 1512762. Its filings are on SEC EDGAR.

How many shares does Coherus Oncology have outstanding?

154,500,966 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.

Which country or territory is Coherus Oncology listed under?

Our directory records Coherus Oncology, Inc. under United States.

What does Coherus Oncology do?

Our directory classifies Coherus Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Coherus Oncology?

The ISIN recorded for Coherus Oncology, Inc. is US19249H1032.

Does aibio.space cover Coherus Oncology?

aibio.space lists Coherus Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Coherus Oncology incorporated?

SEC records list its state or country of incorporation as DE.

What does Coherus Oncology develop?

Coherus Oncology, Inc. is a fully integrated commercial-stage oncology company focused on immuno-oncology. Its approved product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody developed with Junshi Biosciences Co., Ltd. The company announced on October 27, 2023 that the FDA had approved LOQTORZI for first-line nasopharyngeal carcinoma (NPC) with cisplatin and gemcitabine and as monotherapy for recurrent or metastatic NPC after platinum-containing chemotherapy.

What is LOQTORZI (toripalimab-tpzi) from Coherus Oncology?

LOQTORZI (toripalimab-tpzi): Anti-PD-1 antibody for nasopharyngeal carcinoma Stage: approved in the US.

What is Casdozokitug (CHS-388) from Coherus Oncology?

Casdozokitug (CHS-388): IL-27 antagonist antibody for hepatocellular carcinoma and other cancers Stage: randomized Phase 2.

## Investor discussion: Coherus Oncology

Members talk about Coherus Oncology (CHRS). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Coherus Oncology, newest first. Each line links the filing it comes from.

1. 2026-08-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465926103241/tm2623944-1_424b5.htm)
2. 2026-08-17 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465926097949/chrs-20260817x8k.htm)
3. 2026-06-15 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/chrs-20260612x8k.htm)
4. 2026-02-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465926014280/tm265579-1_424b5.htm)
5. 2026-01-23 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465926006306/tm263459-1_424b5.htm)
6. 2025-09-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000155837025011911/chrs-20250905x8k.htm)
7. 2025-07-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000155837025009085/chrs-20250630x8k.htm)
8. 2025-04-16 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465925035503/tm2512297-1_sctoi.htm)
9. 2025-04-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/chrs-20250411xex99d1.htm)
10. 2025-04-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/chrs-20250331xex99d1.htm)
11. 2025-01-14 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465925003440/tm2429853-6_prem14a.htm)
12. 2024-12-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/tm2429853d1_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CHRS on TradingView](https://www.tradingview.com/symbols/NASDAQ-CHRS/).

## SEC filings and registration

- **SEC name**: Coherus Oncology, Inc.

- **CIK**: 1512762

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: CHRS (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Accelerated filer<br>Smaller reporting company

- **Business address**: C/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065

- **Phone**: (650) 649-3530

- **Shares outstanding**: 154,500,966 as of 2026-07-31 (10-Q filed 2026-08-05)

- **Former names**: Coherus BioSciences, Inc.; BioGenerics, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/chrs-20260828x8k.htm) filed 2026-08-28
- [424B5](https://www.sec.gov/Archives/edgar/data/1512762/000110465926103241/tm2623944-1_424b5.htm) filed 2026-08-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/chrs-20260817x8k.htm) filed 2026-08-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926097949/chrs-20260817x8k.htm) filed 2026-08-17
- [10-Q](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/chrs-20260630x10q.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/chrs-20260612x8k.htm) filed 2026-06-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/chrs-20260527x8k.htm) filed 2026-06-01

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001512762), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Coherus Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CHRS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Coherus Oncology, Inc.

- **Ticker**: CHRS

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US19249H1032

- **Other listed symbols**: GETTEX:8C5; LSX:A12ETZ

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CHRS/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/coherus-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Coherus Oncology (CHRS) news: convertible notes and Nasdaq notice", 2026-10-31, https://aibio.space/companies/coherus-oncology/